{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:58:41Z","timestamp":1793649521092,"version":"4.5.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100735"],"award-info":[{"award-number":["82100735"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dalian Municipal Paramount Project Grant","award":["2023DF001"],"award-info":[{"award-number":["2023DF001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27239-8","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T11:27:35Z","timestamp":1765193255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Triple therapy of RAS inhibitors, dapagliflozin, and finerenone in diabetic kidney disease patients with nephrotic-range proteinuria: a real-world study"],"prefix":"10.1038","volume":"15","author":[{"given":"Chenjie","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"27239_CR1","doi-asserted-by":"publisher","unstructured":"Kovesdy, C. P. Epidemiology of chronic kidney disease: an update 2022. Kidney Int. Suppl.   12, 7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003 (2022).","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"27239_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.mcna.2023.03.004","volume":"107","author":"S Gupta","year":"2023","unstructured":"Gupta, S., Dominguez, M. & Golestaneh, L. Diabetic kidney disease: an update. Med. Clin. North. Am. 107, 689\u2013705. https:\/\/doi.org\/10.1016\/j.mcna.2023.03.004 (2023).","journal-title":"Med. Clin. North. Am."},{"key":"27239_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2337\/dc20-1913","volume":"44","author":"HT Cheng","year":"2021","unstructured":"Cheng, H. T., Xu, X., Lim, P. S. & Hung, K. Y. Worldwide epidemiology of Diabetes-Related End-Stage renal Disease, 2000\u20132015. Diabetes Care. 44, 89\u201397. https:\/\/doi.org\/10.2337\/dc20-1913 (2021).","journal-title":"Diabetes Care"},{"key":"27239_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1053\/j.ackd.2011.04.002","volume":"18","author":"MJ Sarnak","year":"2011","unstructured":"Sarnak, M. J. & Astor, B. C. Implications of proteinuria: CKD progression and cardiovascular outcomes. Adv. Chronic Kidney Dis. 18, 258\u2013266. https:\/\/doi.org\/10.1053\/j.ackd.2011.04.002 (2011).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"27239_CR5","doi-asserted-by":"publisher","first-page":"e62143","DOI":"10.7759\/cureus.62143","volume":"16","author":"S Nagaram","year":"2024","unstructured":"Nagaram, S. et al. Prognostic impact of proteinuria at manifestation in adult nephrotic syndrome patients: insights from a prospective cohort study. Cureus 16, e62143. https:\/\/doi.org\/10.7759\/cureus.62143 (2024).","journal-title":"Cureus"},{"key":"27239_CR6","doi-asserted-by":"publisher","first-page":"e0190493","DOI":"10.1371\/journal.pone.0190493","volume":"13","author":"S Iimori","year":"2018","unstructured":"Iimori, S. et al. Prognosis of chronic kidney disease with normal-range proteinuria: the CKD-ROUTE study. PLoS One. 13, e0190493. https:\/\/doi.org\/10.1371\/journal.pone.0190493 (2018).","journal-title":"PLoS One"},{"key":"27239_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27239_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"27239_CR9","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27239_CR10","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956 (2021).","journal-title":"N. Engl. J. Med."},{"key":"27239_CR11","doi-asserted-by":"publisher","first-page":"sfad285","DOI":"10.1093\/ckj\/sfad285","volume":"17","author":"JJ Neumiller","year":"2024","unstructured":"Neumiller, J. J., Alicic, R. Z. & Tuttle, K. R. Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease. Clin. Kidney J. 17, sfad285. https:\/\/doi.org\/10.1093\/ckj\/sfad285 (2024).","journal-title":"Clin. Kidney J."},{"key":"27239_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/ndt\/gfab167","volume":"38","author":"A Ortiz","year":"2023","unstructured":"Ortiz, A. et al. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrol. Dia. Transplant. Off. Publ. Eur. Dialysis Transpl. Assoc. Eur. Ren. Assoc.. 38, 10\u201325. https:\/\/doi.org\/10.1093\/ndt\/gfab167 (2023).","journal-title":"Nephrol. Dia. Transplant. Off. Publ. Eur. Dialysis Transpl. Assoc. Eur. Ren. Assoc."},{"key":"27239_CR13","doi-asserted-by":"publisher","first-page":"2400541","DOI":"10.1080\/0886022X.2024.2400541","volume":"46","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China. Ren. Fail. 46, 2400541. https:\/\/doi.org\/10.1080\/0886022X.2024.2400541 (2024).","journal-title":"Ren. Fail."},{"key":"27239_CR14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s10157-015-1094-2","volume":"19","author":"Y Kitai","year":"2015","unstructured":"Kitai, Y. et al. Nephrotic range proteinuria as a strong risk factor for rapid renal function decline during pre-dialysis phase in type 2 diabetic patients with severely impaired renal function. Clin. Exp. Nephrol. 19, 1037\u20131043. https:\/\/doi.org\/10.1007\/s10157-015-1094-2 (2015).","journal-title":"Clin. Exp. Nephrol."},{"key":"27239_CR15","doi-asserted-by":"publisher","first-page":"101240","DOI":"10.1016\/j.eclinm.2021.101240","volume":"43","author":"P Ruggenenti","year":"2022","unstructured":"Ruggenenti, P. et al. Nephrotic-range proteinuria in type 2 diabetes: effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine 43, 101240. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101240 (2022).","journal-title":"EClinicalMedicine"},{"key":"27239_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/ckj\/sfac189","volume":"16","author":"Z Kalay","year":"2023","unstructured":"Kalay, Z. et al. SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence. Clin. Kidney J. 16, 52\u201360. https:\/\/doi.org\/10.1093\/ckj\/sfac189 (2023).","journal-title":"Clin. Kidney J."},{"key":"27239_CR17","doi-asserted-by":"publisher","unstructured":"van Mil, D. et al. Early changes, and residual albuminuria: post hoc analysis of a randomized clinical trial of Dapagliflozin in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 19, 1574\u20131584. https:\/\/doi.org\/10.2215\/CJN.0000000000000550 (2024). Baseline.","DOI":"10.2215\/CJN.0000000000000550"},{"key":"27239_CR18","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","volume":"6","author":"PI Georgianos","year":"2021","unstructured":"Georgianos, P. I. & Agarwal, R. Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int. Rep. 6, 2281\u20132291. https:\/\/doi.org\/10.1016\/j.ekir.2021.05.027 (2021).","journal-title":"Kidney Int. Rep."},{"key":"27239_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","volume":"7","author":"P Rossing","year":"2022","unstructured":"Rossing, P. et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without Sodium-Glucose Cotransporter-2 inhibitor therapy. Kidney Int. Rep. 7, 36\u201345. https:\/\/doi.org\/10.1016\/j.ekir.2021.10.008 (2022).","journal-title":"Kidney Int. Rep."},{"key":"27239_CR20","doi-asserted-by":"publisher","first-page":"e230453","DOI":"10.1001\/jamanetworkopen.2023.0453","volume":"6","author":"MC Chung","year":"2023","unstructured":"Chung, M. C. et al. Sodium-Glucose transport protein 2 inhibitor use for type 2 diabetes and the incidence of acute kidney injury in Taiwan. JAMA Netw. Open. 6, e230453. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.0453 (2023).","journal-title":"JAMA Netw. Open."},{"key":"27239_CR21","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing, P. et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by Sodium-Glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care. 45, 2991\u20132998. https:\/\/doi.org\/10.2337\/dc22-0294 (2022).","journal-title":"Diabetes Care"},{"key":"27239_CR22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474\u2013484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777 (2022).","journal-title":"Eur. Heart J."},{"key":"27239_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/ckj\/sfad082","volume":"16","author":"B Fern\u00e1ndez-Fernandez","year":"2023","unstructured":"Fern\u00e1ndez-Fernandez, B., Sarafidis, P., Soler, M. J. & Ortiz, A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin. Kidney J. 16, 1187\u20131198. https:\/\/doi.org\/10.1093\/ckj\/sfad082 (2023).","journal-title":"Clin. Kidney J."},{"key":"27239_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s2213-8587(23)00321-2","volume":"12","author":"Effects of empagliflozin on progression of chronic","year":"2024","unstructured":"Effects of empagliflozin on progression of chronic. Kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabets Endocrionol. 12, 39\u201350. https:\/\/doi.org\/10.1016\/s2213-8587(23)00321-2 (2024).","journal-title":"Lancet Diabets Endocrionol."},{"key":"27239_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1681\/ASN.2016060666","volume":"28","author":"L Tonneijck","year":"2017","unstructured":"Tonneijck, L. et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical Significance, and treatment. J. Am. Soc. Nephrol. 28, 1023\u20131039. https:\/\/doi.org\/10.1681\/ASN.2016060666 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"27239_CR26","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink, H. J., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney Effects, potential Mechanisms, and clinical applications. Circulation 134, 752\u2013772. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021887 (2016).","journal-title":"Circulation"},{"key":"27239_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune, J. et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension 71, 599\u2013608. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10360 (2018).","journal-title":"Hypertension"},{"key":"27239_CR28","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12882-024-03652-5","volume":"25","author":"MS Khan","year":"2024","unstructured":"Khan, M. S. & Lea, J. P. Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes. BMC Nephrol. 25, 248. https:\/\/doi.org\/10.1186\/s12882-024-03652-5 (2024).","journal-title":"BMC Nephrol."},{"key":"27239_CR29","doi-asserted-by":"publisher","unstructured":"Crompton, M. et al. Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx. JCI Insight. 8, 2563.  https:\/\/doi.org\/10.1172\/jci.insight.154164 (2023).","DOI":"10.1172\/jci.insight.154164"},{"key":"27239_CR30","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","volume":"46","author":"SC Naaman","year":"2023","unstructured":"Naaman, S. C. & Bakris, G. L. Diabetic nephropathy: update on pillars of therapy slowing progression. Diabetes Care. 46, 1574\u20131586. https:\/\/doi.org\/10.2337\/dci23-0030 (2023).","journal-title":"Diabetes Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27239-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27239-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27239-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T11:27:36Z","timestamp":1765193256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27239-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27239"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27239-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43315"}}